Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Côme Bommier, Mazie Tsang, Brie N. Noble, Carrie Thompson, Christopher Strouse, Carla Casulo, Eric Mou, Melissa C. Larson, Brianna Gysbers, Allison C. Rosenthal, Andrew L. Feldman, Matthew J. Maurer, Kathleen Yost, Susan L. Slager, Brian K. Link, Thomas M. Habermann, Amylou Constance Dueck, James R. Cerhan

Blood (2023) 142 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2023-186862

Published: 2023

Journal Articles

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

Kittika Poonsombudlert, Sarah L Mott, Brenda Miller, Hira Shaikh, Christopher Strouse, Jonathan Lochner, Umar Farooq, Margarida Magalhaes-Silverman

Blood (2023) 142 (Supplement 1): 2174.

https://doi.org/10.1182/blood-2023-181780

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Christopher Strouse, Mark Juckett, Brent R. Logan, Noel Estrada-Merly, Jaime M. Preussler, Tony Truong, Jesse Troy, Nandita Khera, William Wood, Hemalatha G. Rangarajan, Luke Akard, Neel S. Bhatt, Akshay Sharma, Wael Saber

Blood (2023) 142 (Supplement 1): 373.

https://doi.org/10.1182/blood-2023-182013

Published: 2023

Journal Articles

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, Brie N. Noble, Timothy G. Call, Sameer A. Parikh, Tait D. Shanafelt, Mazie Tsang, Côme Bommier, Kari G. Rabe, Christopher Strouse, Carrie Thompson, Paul J. Hampel, Kathleen Yost, Melissa C. Larson, Susan L. Slager, Brian K. Link, James R. Cerhan, Amylou Constance Dueck

Blood (2023) 142 (Supplement 1): 498.

https://doi.org/10.1182/blood-2023-187268

Published: 2023

Journal Articles

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Blood (2023) 142 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2023-187056

Published: 2023

Journal Articles

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Aytaj Mammadzadeh, Yara Shatnawi, Rawan Atallah, Benlazar Mohamed, Nihar Desai, Shahrukh K Hashmi, Thiago Xavier Carneiro, Hira Shaikh, Christopher Strouse, Rakesh Popat, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4727.

https://doi.org/10.1182/blood-2023-185151

Published: 2023

Journal Articles

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Blood (2023) 142 (Supplement 1): 3761.

https://doi.org/10.1182/blood-2023-188382

Published: 2023

Journal Articles

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Priyanka Venkatesh, Sara Shatnawi, Yara Shatnawi, Hira Shaikh, Christopher Strouse, Shebli Atrash, Muhammad Umair Mushtaq, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Leyla Shune

Blood (2023) 142 (Supplement 1): 6694.

https://doi.org/10.1182/blood-2023-187652

Published: 2023

Journal Articles

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Jr., Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 91.

https://doi.org/10.1182/blood-2023-180421

Published: 2023

Journal Articles

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2023) 141 (15): 1888–1893.

https://doi.org/10.1182/blood.2022019294

Published: 2023

Includes: Supplemental data

Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 10160–10162.

https://doi.org/10.1182/blood-2022-157347

Published: 2022

Journal Articles

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Juan Pablo Alderuccio, Isildinha M Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R Chapman-Fredricks, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2022) 140 (Supplement 1): 9340–9341.

https://doi.org/10.1182/blood-2022-162688

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-136551

Published: 2020

Journal Articles

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Arushi Khurana, MBBS, Raphael Mwangi, Stephen M. Ansell, MD PhD, Thomas M. Habermann, MD, James R. Cerhan, MD PhD, Christopher Strouse, MD, Brian K. Link, MD, Yucai Wang, MDPhD, Rebecca L. King, MD, William R. Macon, MD, Jose C Villasboas, MD, Thomas E. Witzig, MD, Matthew J. Maurer, MS, Grzegorz S. Nowakowski, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141011

Published: 2020

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 1553.

https://doi.org/10.1182/blood-2019-131276

Published: 2019

Journal Articles

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Blood (2019) 134 (Supplement_1): 1610.

https://doi.org/10.1182/blood-2019-126068

Published: 2019

NARROW

Impact of Frontline Treatment Strategy on Quality of Life in the First Decade after a Diagnosis of Marginal Zone Lymphoma

Clinical Outcomes of Patients Receiving 3 Versus 4 Doses of Methotrexate with Concomitant Anti-Thymocyte Globulin; A Single Center Experience

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Lymphoma-Related Quality of Life (QOL) Is Not Impacted By Initial Treatment Choice in Patients with Marginal Zone Lymphoma (MZL): Results from the Prospective Lymphoma Epidemiology of Outcomes (LEO) Cohort

Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Frontline Management Strategy and Quality of Life in Follicular Lymphoma: A Multi-Institutional Prospective Cohort Study

Vdpace As Salvage Therapy in Triple Class Relapse/Refractory Multiple Myeloma

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era

Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only